Lyell Immunopharma (LYEL) announced that Lynn Seely, MD, a member of the company’s board and former president and chief executive officer, CEO, of Myovant Sciences (MYOV), has been named Lyell’s president & CEO effective today. Dr. Seely succeeds Ms. Liz Homans following a four-year tenure as president and then CEO. Homans will remain a consultant to the company through June 2024.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on LYEL:
- Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer
- Lyell Immunopharma to Participate in BofA Securities Biotech Conference
- Lyell Immunopharma downgraded to Equal Weight from Overweight at Morgan Stanley
- Lyell Immunopharma to Participate in Barclays Virtual Fireside Chat Series
- Lyell Immunopharma price target lowered to $11 from $12 at H.C. Wainwright
